Inhibrx Biosciences Inc.

INBX

$113.00

Updated: 22/09/2026, 20:04:44

Market Cap

$1.66B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for INBX

Company Profile

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

USD

NASDAQ

CEO: Mark Lappe

Employees: 110

https://www.inhibrx.com

Asset Summaries

Latest generated summaries for INBX

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for INBX.

Share price: $113.00
Market cap: $1.66B
Exchange: NASDAQ
Currency: USD
CEO: Mark Lappe
Employees: 110
IPO date: 29/05/2024
Beta: 3.671
Last dividend: $0.00
Day range: $110.95 – $117.14
52-week range: $27.12 – $155.29
1-day performance: 0.86%
1-year performance: 316.68%
Current drawdown (1Y): -27.23%
CIK: 0002007919
CUSIP: 45720N103
ISIN: US45720N1037
Created: 07/12/2025, 04:43:36
Last update: 22/09/2026, 20:04:44

Track Inhibrx Biosciences Inc. with an AI analyst

See which prediction-market events move INBX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to INBX from your Railway `news_articles` table.

Inhibrx Reports First Quarter 2026 Financial Results

PRNewsWire • STOCK • 14/05/2026, 18:02:00

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Benzinga • STOCK • 11/05/2026, 15:57:59

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

MarketBeat • STOCK • 11/05/2026, 14:09:25

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Seeking Alpha • STOCK • 22/04/2026, 19:36:07

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Reuters • STOCK • 22/04/2026, 09:02:31

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

PRNewsWire • STOCK • 20/04/2026, 19:03:00

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

PRNewsWire • STOCK • 19/03/2026, 17:00:00

Inhibrx Announces Participation in Upcoming Scientific Conference

PRNewsWire • STOCK • 02/03/2026, 17:00:00